Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting : Episode 9

Opinion

Video

April 25, 2024

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

EP: 1.Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

EP: 2.Selecting Optimal 3L Colorectal Cancer Treatment

EP: 3.Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

EP: 4.General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

EP: 5.Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

EP: 6.Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

EP: 7.Treatment Considerations With Regorafenib in Colorectal Cancer

EP: 8.Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

Now Viewing

EP: 9.FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

EP: 10.Monitoring and AE Management Strategies with Fruquintinib in CRC

EP: 11.Toxicity Considerations and Treatment Decisions in CRC

EP: 12.Multidisciplinary Care for Patients with CRC

EP: 13.Unmet Needs and Future Perspectives in Colorectal Cancer

Related Content

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center

November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

November 20th 2024

Phase 3 Trial Data Inform Advancements in Targeted Therapy for Gastric/GEJ Cancers

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

November 18th 2024

Zolbetuximab Approval Paves Way for Precision Medicine in Gastric and GEJ Adenocarcinoma

November 17th 2024

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer